In its Q1 earnings release, Corvus Pharmaceuticals Inc (NASDAQ: CRVS) revealed updated data from the Phase 1/1b trial evaluating single-agent therapy with CPI-818 in patients with
Blockstream CEO Adam Back, has expressed his confidence in Bitcoin (CRYPTO: BTC) reaching a new all-time high of over $100,000 before the cryptocurrency’s halving event in 2024.